The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet
-
- Shimizu Ryo
- Department of Hematology, Chiba University Hospital, Japan
-
- Ohwada Chikako
- Department of Hematology, Chiba University Hospital, Japan
-
- Nagao Yuhei
- Department of Hematology, Chiba University Hospital, Japan
-
- Togasaki Emi
- Department of Hematology, Chiba University Hospital, Japan
-
- Kawajiri Chika
- Department of Hematology, Chiba University Hospital, Japan
-
- Muto Tomoya
- Department of Hematology, Chiba University Hospital, Japan
-
- Tsukamoto Shokichi
- Department of Hematology, Chiba University Hospital, Japan
-
- Sakai Shio
- Department of Hematology, Chiba University Hospital, Japan Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan
-
- Takeda Yusuke
- Department of Hematology, Chiba University Hospital, Japan
-
- Mimura Naoya
- Department of Hematology, Chiba University Hospital, Japan Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan
-
- Takeuchi Masahiro
- Department of Hematology, Chiba University Hospital, Japan
-
- Sakaida Emiko
- Department of Hematology, Chiba University Hospital, Japan
-
- Iseki Tohru
- Department of Hematology, Chiba University Hospital, Japan Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan
-
- Nakaseko Chiaki
- Department of Hematology, Chiba University Hospital, Japan
この論文をさがす
抄録
<p>Infections of the central nervous system (CNS) with varicella zoster virus (VZV) is a rare occurrence after allogeneic hematopoietic stem cell transplantation. We herein report a case of VZV meningitis, radiculitis and myelitis that developed 8 months after cord blood transplantation, shortly after the cessation of cyclosporine and low-dose acyclovir. Although treatment with acyclovir did not achieve a satisfactory response, the patient was successfully treated with foscarnet. Our report indicates that VZV infection should be considered in allo-hematopoietic stem cell transplantation (HSCT) patients with CNS symptoms and that foscarnet may be effective for the treatment of acyclovir-resistant VZV infections of the CNS. The development of optimal prophylactic strategies and vaccination schedules may eradicate post-transplant VZV disease. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 56 (3), 353-356, 2017
一般社団法人 日本内科学会